ClinicalTrials.gg
CompletedNCT07273539Updated Mar 11, 2026

A Study to Evaluate the Effect of a Test (Sodium Bicarbonate) Toothpaste on the Oral Microbiome

An interventional study of Sodium Bicarbonate Toothpaste and Sodium Fluoride Toothpaste in Gingivitis, sponsored by HALEON. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by HALEON · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Gingivitis by HALEON — 2 open to participants now, 2 under way, none of them phase 3. Gingivitis · HALEON.

Enrollment
10th of 12
74 · median 146
Started
2025
with 3 others
No phase
11 of 12
2 open now
Registered
9th of 12
by date

Among the 12 studies in Gingivitis by HALEON, this one is the 10th largest by enrollment, is one of 4 that started in 2025, is one of 11 with no phase, and was the 9th registered.

Gingivitis

635 studies on the registry are indexed under Gingivitis; 109 are open to participants now.

Browse Gingivitis studies →

Open to participants now

2 of the 12 studies in Gingivitis by HALEON are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 54 Gingivitis studies recruiting now, 16 (30%) set no upper age limit and 36 (67%) stop at 75 or younger; 11 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Gingivitis by HALEON, or all of them as a file.
02

Study summary

The aim of this 12-week clinical study is to evaluate the effect of a toothpaste containing sodium bicarbonate over time on the oral microbiome and to explore its effect in comparison to a regular fluoride toothpaste in participants with localized gingivitis.

Read the detailed description

This will be a single-center, 12-week, randomized, controlled, single-blind (examiner only), two-treatment arm, parallel group design, clinical study investigating the effect of a toothpaste containing sodium bicarbonate on the oral microbiome in healthy adult participants with mild-moderate gingivitis. Approximately 55 participants (approximately 27 per group) will be randomized to ensure approximately 50 evaluable participants (approximately 25 per group) complete the study.

03

Conditions studied

  • Gingivitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant provision of a signed and dated document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • Participant's biological sex at birth was male or female.
  • Participant who, at the time of screening is aged 18-65 years, inclusive.
  • A participant who is willing and able to comply with scheduled visits, treatment plan and other study procedures.
  • A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.
  • Participant with at least 20 natural, permanent teeth (excluding 3rd molars) and with at least 40 evaluable surfaces.
  • A healthy participant with mild to moderate gingivitis in the opinion of the clinical examiner.

Exclusion criteria

Exclusion Criteria:

  • A participant who is an employee of the site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
  • A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
  • A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • A participant who has any other clinical serious or unstable conditions (example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) which could have affected study out comes and/or participant safety.
  • A participant who is a pregnant female (self-reported) at screening or baseline visit or intending to become pregnant over the duration of the study or who is breastfeeding.
  • A participant with known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • A participant unwilling or unable to comply with the Lifestyle Considerations described in this protocol (these will be added in the full protocol).
  • A participant who is a current smoker or an ex-smoker (including vaper) who stopped within 6 months of Screening.
  • A participant who is using smokeless forms of tobacco (example, chewing tobacco, gutkha, pan containing tobacco, nicotine-based e-cigarettes).
  • A participant who is diagnosed with oral dryness or is taking any medication that in the view of the investigator is causing oral dryness.
  • A participant who has a medical condition which could have directly influenced gingival bleeding.
  • A participant who has a bleeding disorder that could have affected study outcomes and/or participant safety.
  • A participant who has a recent history (within the last year) of alcohol or other substance abuse.
  • A participant who has a severe oral condition (example, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
  • Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.
  • A participant using any antibiotic and/or probiotic medication within 28 days prior to screening or at any time during the study.
  • Participant who has used an oral care product containing anti-bacterial (example, chlorhexidine), probiotic or other ingredient that, in the opinion of the investigator or dentally qualified designee, could affect plaque formation or gingival health within 4 weeks of Screening or between Screening and the Baseline visit.
  • A participant currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.
  • A participant currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.
  • A participant currently taking a systemic medication (example, anti-inflammatory, anticoagulant, ) or traditional/herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
  • A participant who shows signs of periodontitis or is receiving or has received treatment for periodontal disease (including surgery) within 12 months of Screening.
  • A participant who has gingivitis, which in the opinion of the investigator, is not expected to respond to treatment with an over the counter (OTC) dentifrice.
  • A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
  • A participant who has dentures (partial or full).
  • A participant who has Fixed orthodontic appliances or is undergoing active or recent (within 3 months of Screening) orthodontic treatment, which in the opinion of the investigator, could interfere with study procedures, assessments or outcomes.
  • A participant who has other orthodontic devices (example, bands, fixed retainers, or removable retainers) that could, in the opinion of the investigator, interferes with study procedures, assessment or outcomes.
  • A participant who has numerous restorations in a poor state of repair.
  • A participant who has any dental condition (example, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
  • A participant who has had dental prophylaxis within 12 weeks of Screening.
  • A participant who has had teeth bleaching within 12 weeks of Screening.
  • A participant who has high levels of extrinsic stain or calculus deposits
  • A participant who has previously been enrolled in this study.
  • A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    Test Toothpaste

    Participants will be instructed to brush their teeth with the test toothpaste for at least one minute twice daily (morning and evening) for 12 weeks.

    Drug: Sodium Bicarbonate Toothpaste

  • Active comparator
    Reference Toothpaste

    Participants will be instructed to brush their teeth with the reference toothpaste for at least one minute twice daily (morning and evening) for 12 weeks.

    Drug: Sodium Fluoride Toothpaste

Interventions

  • DrugSodium Bicarbonate Toothpaste

    A toothpaste containing sodium bicarbonate and sodium fluoride.

  • DrugSodium FluorideStudies of Sodium FluorideSodium Fluoride pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A toothpaste containing 0.315 percent (%) weight/weight (w/w) sodium fluoride; 1450 parts per million (ppm) fluoride.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Bacterial Composition at Week 12 by Treatment Groups

    Taxonomic changes of microbial communities in plaque samples will be reported.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Potential Bacterial Activity at Week 12 by Treatment Groups

    Potential functional capabilities of microbial communities in plaque samples will be reported in different areas of plaque.

    Time frame: Baseline and Week 12

  2. Differences in Bacterial Composition at Week 12 (Test Toothpaste Versus (Vs) Control Toothpaste)

    Comparison of bacterial composition in different areas of plaque will be reported.

    Time frame: Week 12

  3. Differences in Bacterial Composition Between Different Areas of Plaque at Week 12

    Comparison of bacterial composition in different areas of plaque will be reported for test and reference toothpaste.

    Time frame: Week 12

07

Study locations

1 site
  • University of Birmingham
    Birmingham, B5 7EG, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Feb 2026, 4 months.

Of 53 industry-sponsored interventional studies with no phase under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 5. This study's 4 months is above that.

Counting every sponsor, half of 259 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 9, 2025
StartActual
Oct 27, 2025
Primary completionActual
Feb 27, 2026
CompletionActual
Feb 27, 2026
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07273539
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Dec 9, 2025
Start date
Oct 27, 2025
Primary completion
Feb 27, 2026
Completion
Feb 27, 2026
Last update
Mar 11, 2026

Study contacts

Praveen Sharma
principal investigator · University of Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion